1. Early Stem Cell Transplantation for Refractory Acute Leukemia after Salvage Therapy with High-Dose Etoposide and Cyclophosphamide 
Asha Johny, Kevin W. Song, Stephen H. Nantel, Julye C. Lavoie, Cynthia L. Toze, Donna E. Hogge, Donna L. Forrest, Heather J. Sutherland, Alan Le, Janet Y. Nitta, Michael J. Barnett, Clayton A. Smith, John D. Shepherd, Thomas J. Nevill 
Biology of Blood and Marrow Transplantation 
Volume 12, Issue 4, Pages (April 2006)
DOI: /j.bbmt
Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Event-free survival for 29 patients who underwent allogeneic stem cell transplantation after etoposide and cyclophosphamide salvage for primary refractory leukemia (median follow-up, 11 months).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Event-free survival for 16 patients with primary refractory acute myelogenous leukemia who underwent allogeneic stem cell transplantation in first complete remission after etoposide and cyclophosphamide salvage therapy (median follow-up, 11 months).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
Event-free survival for patients who underwent allogeneic stem cell transplantation after etoposide and cyclophosphamide salvage according to type of leukemia (median follow-up, 11 months).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions

5. Figure 4
Event-free survival for 59 patients with primary refractory acute leukemia treated with etoposide and cyclophosphamide salvage therapy (median follow-up, 11 months).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions

6. Figure 5
Event-free survival for patients with primary refractory acute leukemia treated with etoposide and cyclophosphamide salvage therapy according to cytogenetic risk group (median follow-up, 11 months).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions